Oncology Stocks Surge on mRNA-Based Vaccine Success

Pfizer Inc. (PFE) shares rallied earlier this week alongside Moderna (MRNA) and partner Merck (MRK), after positive Phase 3 results for their mRNA-based vaccine in melanoma treatment.

The vaccine's success has sparked interest in the oncology sector, with some analysts weighing in on promising companies.

Stephen Ayers from ALLKA Research and Gen Pro share their views on the most promising oncology companies currently. They include Pfizer (PFE), Johnson & Johnson (JNJ), Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT), Merck (MRK), and several others.

These companies have been making strides in cancer treatment, with some already seeing significant gains from their research. However, it's essential to note that investing in the healthcare sector comes with its own set of risks and challenges.